RxDoctor Payments Data

Scott Caldwell

Primary Care · Erie, PANPI 1114435088

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,813 of the $2,098 with a category attached, or 86.4%. Astellas Pharma US Inc accounts for 64.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $575 and has fallen 69.8% since, to $174 in 2025.

$2,098in general payments, 2019–2025

Across 78 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$156
  • Boston Scientific$125
  • Urovant Sciences Inc$75
  • Endo Pharmaceuticals Inc.$57
  • Tolmar Pharmaceuticals, Inc.$56
  • plus $287 from 8 others

What the payments were for

  • Food & beverage$1,81386%
  • Education$28514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,098 in reported general payments places this provider in the 80th percentile of 300 primary care providers in Pennsylvania.

See all primary care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$28,012
Medicare patients
229
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron66$51,304
GemtesaVibegron24$13,486
EliquisApixaban13$7,654
Tamsulosin Hcl416$4,255
Alfuzosin Hcl ErAlfuzosin Hcl67$1,423
Silodosin18$1,410
Testosterone Cypionate50$1,338
Dutasteride18$1,098
Finasteride70$833
Trospium Chloride ErTrospium Chloride11$498
Solifenacin Succinate16$232
Tadalafil15$163
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$113
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$71
Cephalexin19$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,342$51,30466 claims
Sumitomo Pharma America, Inc.Gemtesa$156$13,48624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 primary care providers in Pennsylvania.

Other primary care in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →